| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/06/2010 | US7691993 Fusion proteins of Mycobacterium tuberculosis |
| 04/06/2010 | US7691987 Use of a novel eimeria gene and corresponding protein |
| 04/06/2010 | US7691980 Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| 04/06/2010 | US7691977 Anti-VEGF antibodies |
| 04/06/2010 | US7691973 GFRα3 polypeptides |
| 04/06/2010 | US7691972 three-dimensional structure to design a mutant of a protein belonging to the papain-like cysteine proteases; high degree of purity |
| 04/06/2010 | US7691971 Protein NMB1125 and use thereof in pharmaceutical formulations |
| 04/06/2010 | US7691823 RIP140 regulation of glucose transport |
| 04/06/2010 | US7691804 Administering formulation selected from a BAFF-R polypeptide or fragment; a chimeric molecule comprising a BAFF-R polypeptide or fragment fused to heterologous amino acid sequence; anti-BAFF-R antibody for inhibiting B-cell growth |
| 04/06/2010 | US7691627 Nucleic acid sequences encoding D1 and D1/D2 domains of human coxsackievirus and adenovirus receptor (CAR) |
| 04/06/2010 | US7691606 Soluble GDNFR (Glial-cell Derived Neurotrophic Factor) that retains both ligand binding, and receptor signaling function (via Ret receptor tyrosine kinase) used to impart, restore, or enhance GDNFR alpha -ligand (preferably GDNF) responsiveness to cells; kidney diseases |
| 04/06/2010 | US7691572 Method and kit for detecting resistance to antiviral drugs |
| 04/06/2010 | US7691568 Antibody composition-containing medicament |
| 04/06/2010 | US7691566 Compositions and methods for treatment of cancer |
| 04/06/2010 | US7691396 Chimeric peptides comprising HER-2 B-cell epitopes and measles virus fusion protein T-cell epitopes |
| 04/06/2010 | US7691395 BASB119 polypeptide and polynucleotide from Moraxella catarrhalis |
| 04/06/2010 | US7691393 Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the Listeria, and methods of use thereof |
| 04/06/2010 | US7691391 Monoparamunity inducers based on attenuated rabbit myxomaviruses |
| 04/06/2010 | US7691390 polypeptide and isolated nucleic acid encoding the polypeptide for SARS CoV protein 3a, which can serve as a target for elucidating the mechanisms of SARS and developing vaccines and therapeutics |
| 04/06/2010 | US7691389 Infectious cDNA clone of north american porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof |
| 04/06/2010 | US7691386 comprising a papillomavirus L1 product and a papillomavirus L2 fusion product; drug delivery |
| 04/06/2010 | US7691385 Polypeptides encoded by polynucleotides that are useful for detecting resistance to streptogramin A or to streptogramin B and related compounds |
| 04/06/2010 | US7691384 using a human Fc epsilon receptor (Fc68 R) to detect epsilon immunoglobulin (IgE); detecting a plant allergy in a canid, felid or equid |
| 04/06/2010 | US7691383 Peptide facilitating the entry of a linked molecule into a mammalian cancer cell |
| 04/06/2010 | US7691382 Antiviral polypeptides comprising tandem repeats of APOE 141-149 and variants thereof |
| 04/06/2010 | US7691381 implants containing a neurotoxin with sustained biological activity would manifest as improved patient compliance, increased quality of life, improved therapeutic outcome and a reduced incidence of side effects and complications |
| 04/06/2010 | US7691380 Coagulating the vascular systems of cancer cells through site specific delivery of coagulant antibodies causing regression of the cells |
| 04/06/2010 | US7691379 Anti-IL-9 antibody formulations |
| 04/06/2010 | US7691378 Treating carcinomas or adenocarcinomas using at least one anti-TNF (tumor necrosis factor) antibody |
| 04/06/2010 | US7691377 Administering glutamate release inhibitor and glutamate receptor antagonist; antiapoptosis |
| 04/06/2010 | US7691376 monoclonal antibodies or fragment thereof which binds a cell surface glycoprotein antigen located on the surface of human multiple myeloma tumor cells; for therapeutic, screening, diagnostic and cell purification purposes |
| 04/06/2010 | US7691375 Treating renal clear cell carcinoma; administration of G250-antigen-specific antibodies to high-risk patients diagnosed with non-metastasizing disease; lymphadenectomy |
| 04/06/2010 | US7691374 Method for increasing the efficacy of anti-tumor agents by anti-endoglin antibody |
| 04/06/2010 | US7691373 Antibody that binds to mammalian Dendritic Cell Membrane Protein (DCMP) genes; immunostimulants |
| 04/06/2010 | US7691372 contains the idiotype of the HE2 antibody directed against the cellular membrane antigen Ep-CAM |
| 04/06/2010 | US7691368 Vaccine formulations |
| 04/06/2010 | CA2378925C Matrix-targeted fusion polypeptides for tissue regeneration and wound healing |
| 04/06/2010 | CA2361582C Immunological adjuvant compound |
| 04/06/2010 | CA2331274C Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof |
| 04/06/2010 | CA2280930C Protein markers for lung cancer and use thereof |
| 04/06/2010 | CA2252466C Hepatitis b monoclonal antibodies |
| 04/06/2010 | CA2193491C Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
| 04/06/2010 | CA2188919C Monoclonal antibodies which promote central nervous system remyelination |
| 04/03/2010 | CA2640416A1 Bifunctional fusion molecules for the delivery of antigens to professional antigen-presenting cells |
| 04/01/2010 | WO2010037095A2 Agents and methods for the treatment of cancer |
| 04/01/2010 | WO2010037063A2 Plasmodium vaccines, antigens, compositions and methods |
| 04/01/2010 | WO2010037046A1 Humanized neuraminidase antibody and methods of use thereof |
| 04/01/2010 | WO2010037041A2 Frizzled-binding agents and uses thereof |
| 04/01/2010 | WO2010037027A2 Immunization of avians by mucosal administration of non-replicating vectored vaccines |
| 04/01/2010 | WO2010036970A2 Influenza vaccines, antigens, compositions, and methods |
| 04/01/2010 | WO2010036959A2 Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| 04/01/2010 | WO2010036948A2 Dna prime/inactivated vaccine boost immunization to influenza virus |
| 04/01/2010 | WO2010036774A1 Methods for purification of viruses |
| 04/01/2010 | WO2010036652A1 Cancer vaccines against mucosal antigens and methods of making and using the same |
| 04/01/2010 | WO2010036460A2 Anti-cd147 antibodies, methods, and uses |
| 04/01/2010 | WO2010036293A1 Malaria vaccine |
| 04/01/2010 | WO2010036230A1 Process for treatment of rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis and non-viral based cancers |
| 04/01/2010 | WO2010036226A1 Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis |
| 04/01/2010 | WO2010036146A1 Use of fc fragments of class g immunoglobulin as an antigen for treating rheumatoid arthritis, agent and method of treatment |
| 04/01/2010 | WO2010035769A1 Improved antibody molecule |
| 04/01/2010 | WO2010035292A1 The use of a human monoclonal anti-hcv antibody as a medicament for the therapeutic treatment and prevention of hcv infections |
| 04/01/2010 | WO2010035119A2 Vaccine adjuvants |
| 04/01/2010 | WO2010035076A1 Individual 5-fluorouracile dose optimization in folfiri treatment |
| 04/01/2010 | WO2010034700A1 Treating cancer by modulating rna helicases |
| 04/01/2010 | WO2010034670A2 Host cell kinases as targets for antiviral therapies against hcv infection |
| 04/01/2010 | WO2010034590A1 Composition for treating disease |
| 04/01/2010 | WO2010034155A1 Kit by detecting egfl7 in samples for the diagnosis of hepatocellular carcinoma and its application |
| 04/01/2010 | WO2010017514A3 Methods of predicting cancer lethality using replikin counts |
| 04/01/2010 | WO2010017103A3 Fully human anti-human nkg2d monoclonal antibodies |
| 04/01/2010 | WO2010014913A8 Toll-like receptor agonist formulations and their use |
| 04/01/2010 | WO2010003101A3 Il6 immunotherapeutics |
| 04/01/2010 | WO2010003057A3 Treating cancer |
| 04/01/2010 | WO2010002867A8 Multivalent antihelminthic vaccine |
| 04/01/2010 | WO2009155724A3 Stable and soluble antibodies inhibiting vegf |
| 04/01/2010 | WO2009151620A9 Pain treatment using erk2 inhibitors |
| 04/01/2010 | WO2009150539A3 Variable domains of camelid heavy-chain antibodies directed against androctonus autralis hector toxins |
| 04/01/2010 | WO2009137832A3 Autoantibodies in the detection and treatment of cancer |
| 04/01/2010 | WO2009133521A3 Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders |
| 04/01/2010 | WO2009109428A3 Self-assembling peptide nanoparticles useful as vaccines |
| 04/01/2010 | WO2009094751A8 An anti-cancer cytotoxic monoclonal antibody |
| 04/01/2010 | WO2009086952A3 Compositions for the treatment of degenerative articular diseases |
| 04/01/2010 | WO2009010614A8 Use of a new isolate of neospora caninum for the development of diagnostic tests and for preparation of products for treatment and prevention of the infection caused by neospora |
| 04/01/2010 | US20100081797 Manipulation of Cytokine Levels Using CD83 Gene Products |
| 04/01/2010 | US20100081793 Therapeutic uses of humanized antibodies against alpha-4 integrin |
| 04/01/2010 | US20100081616 Extracellular matrix-binding proteins from staphylococcus aureus |
| 04/01/2010 | US20100080844 Method to enhance an immune response of nucleic acid vaccination |
| 04/01/2010 | US20100080828 Immunogenic sequences |
| 04/01/2010 | US20100080827 Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents |
| 04/01/2010 | US20100080826 Process for treatment of amyotrophic lateral sclerosis, rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis and non-viral based cancers |
| 04/01/2010 | US20100080825 Filovirus vectors and noninfectious filovirus-based particles |
| 04/01/2010 | US20100080824 A formulation comprising a cell culture extract of an isolated virus is identified to be morphologically and phylogenetically similar to the known member of coronaviruses; kits comprising containers containing the formulation used in medical diagnosis, as vaccines and antibodies |
| 04/01/2010 | US20100080823 Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants |
| 04/01/2010 | US20100080820 Preparation of a Therapeutic Composition |
| 04/01/2010 | US20100080819 Modulators of p-selectin glycoprotein ligand 1 |
| 04/01/2010 | US20100080818 Expression and Characterization of HIV-1 Envelope Protein Associated with Broadly Cross Reactive Neutralizing Antibody Response |
| 04/01/2010 | US20100080817 HUMAN PAPILLOMAVIRUS / Ii-KEY HYBRIDS AND METHODS OF USE |
| 04/01/2010 | US20100080816 Tolerogenic populations of dendritic cells |
| 04/01/2010 | US20100080815 MN Gene and Protein |
| 04/01/2010 | US20100080814 NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS |
| 04/01/2010 | US20100080813 Neutralizing anti-influenza a virus antibodies and uses thereof |